Immunitybio expands manufacturing capacity with state-of-the-art manufacturing plant in new york for global pandemic response and preparedness

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company (“immunitybio”), today announced that it has entered into a definitive agreement to acquire a leasehold interest in 409,000 square feet of iso class 5 pharmaceutical manufacturing space in western new york (the “dunkirk facility”), and certain related assets, from global pharmaceutical company athenex, inc. (nasdaq: atnx) (“athenex”). the agreement will provide immunitybio with a state
IBRX Ratings Summary
IBRX Quant Ranking